We've concluded the questions for today's journal club! Feel free to continue to respond to the questions posted today and engage with colleagues throughout the day. Read the article here: rdcu.be/efSic

#NCSVJC Q4: Given the independently associated longer ICU stay with midazolam, but no difference in mortality, what are the practical and ethical implications of using midazolam as a first-line agent in resource-limited settings? Should ICU LOS be prioritized over mortality in these decisions? rdcu.be/efSic

#NCSVJC Q1: Given that there were no statistically significant differences in IMV duration between sedation strategies after adjustment, how should clinicians interpret these findings in light of prior studies suggesting potential benefits of propofol? Could the lack of difference reflect appropriate titration in neurocritical care settings or limitations in the dataset’s granularity (e.g., sedation depth, dosing protocols)? rdcu.be/efSic

#NCSVJC Q3: Patients sedated with midazolam had significantly higher rates of VAP. Could this be a reflection of the pharmacokinetics of midazolam impeding daily sedation interruption, or might there be confounding variables such as weaning protocols or ICU nurse-to-patient ratios? rdcu.be/efSic

#NCSVJC Q2: The study highlights substantial differences in sedative choice between high-income and middle-income countries. How do you think international guidelines should adapt to these realities—especially considering cost, drug availability, and storage logistics—without inadvertently promoting inequities in care? rdcu.be/efSic

Join us tomorrow on X for #NCSVJC! This month's discussion is on international sedation practices in mechanically ventilated ncc patients, moderated by Dr. Pravin George. Learn more about how to participate: bit.ly/4cbgleW